H.C. Wainwright keeps Buy on Quantum-Si stock at USD 4.00

Published on 10/14/2026 at 02:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Proteus detects 19 amino acids, up from 18 at World HUPO. For Quantum-Si stock, the next target is all 20 by year-end 2026 and a 2027 launch.

Proteus milestones and analyst view

H.C. Wainwright reiterated a Buy rating and a USD 4.00 price target on October 9, 2026.
Quantum-Si demonstrated detection of 19 amino acids on October 8, 2026, after 18 at World HUPO.
The company targets detection of all 20 amino acids by year-end 2026 and a commercial launch in the second quarter of 2027.

QSI, US74765K1051, Illustration mit AI erstellt.

Quantum-Si (ISIN US74765K1051) has a USD 4.00 analyst price target behind its current development story. On October 9, 2026, Investing.com reported that H.C. Wainwright reiterated a Buy rating and a USD 4.00 price target for Quantum-Si, which trades as QSI on Nasdaq.

Three development milestones

Quantum-Si's recent progress forms a clear sequence. On August 13, 2026, the company reported second-quarter revenue of USD 344,000, exceeding the USD 233,800 forecast, while sales declined 41.80 percent from the same period a year earlier, according to Investing.com.

On September 28, 2026, Quantum-Si presented interim Proteus data from a developmental kit detecting 18 amino acids, as listed in the company's investor-relations materials. On October 8, 2026, the program reached 19 amino acids and moved toward deployment in a developmental sequencing kit, according to Yahoo Finance.

What 19 of 20 means

The technical milestone narrows the gap to the company's stated goal of detecting all 20 amino acids by year-end 2026. The next step is practical: Quantum-Si plans to place the 19-amino-acid capability into a developmental kit for routine use on integrated Proteus instruments.

For investors, the distinction between detection capability and routine sequencing remains important. H.C. Wainwright described the update as encouraging while pointing to the need for broader detection to translate into more informative peptide reads and improved protein identification under routine conditions, according to Investing.com.

Launch timing sets the test

Quantum-Si is advancing Proteus toward a commercial launch in the second quarter of 2027, while the company aims to demonstrate all 20 amino acids by year-end 2026. The two milestones give the market a measurable timeline for judging whether laboratory progress becomes a usable sequencing platform.

Upcoming dates for QSI

ToAlpha lists November 5, 2026, as the next earnings date. The planned Proteus commercial launch follows in the second quarter of 2027, according to the company's investor-relations materials.